Hope for new Alzheimers delay drug in bexarotene
The anti-cancer drug bexarotene has been shown to reverse some of the memory defects associated with Alzheimer’s disease in mice expressing a number of the gene mutations associated with the human disorder.
New research from the University of Pittsburgh, and published this week in the journal Science, has shown that the drug has shown “significant improvements” in the cognitive defects often found in patients suffering from Alzheimer’s disease.
The drug has been found to reduce the buildup of plaques of misassembled proteins that aggregate on neurons in the brain, which have long been identified as the cause of the degeneration of nerve tissue that characterizes the disease.
In a series of experiments conducted, mice expressing the Alzheimer’s gene mutation were able to achieve scores that matched those of their non-Alzheimer’s counterparts in cognitive tests after ten days of treatment with the drug.
The tests included tasks intended to determine the mice’s long-term memory by testing their ability to distinguish between two remembered objects following the later introduction of a third novel item.
While it is being stressed that the significance of the findings is not to be exaggerated, Dr Rada Koldamova, the paper’s senior author, does suggest that the work could present “a solid case for continued exploration of bexarotene as a therapeutic treatment for Alzheimer’s disease.”
Alzheimer’s disease is the most common form of dementia, and affects an estimated 26.6 million people worldwide. There is currently no known cure for the disease, which is degenerative and eventually leads to death after an average of seven years of suffering.
Photograph: Stephen Barnett

